PDCD1 and neoplasm: For instance, the combination of pimitespib and PD-1 inhibitors significantly reduced FOXP3-expressing activated Treg cells and improved CD8+ T cell activity through STAT5 degradation in a gastric cancer model, demonstrating significant tumor-suppressive effects compared to monotherapy [122].